A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients
| Autor: | Sabahattin Kaymakoglu, Ahmet Bektaş, Güralp Taşan, Yusuf Erzin, Sule Poturoglu, Ozan Kocakaya, Ender Ellidokuz, Mehmet Derya Onuk, Cengiz Bolukbas, Erol Avsar, Yuksel Ates, Arzu Tiftikçi, Dinc Dincer, Necip Aytuğ, Sefa Güliter, Cansel Türkay, Ugur Yilmaz, Bulut Yıldırım |
|---|---|
| Přispěvatelé: | Ondokuz Mayıs Üniversitesi, Kırıkkale Üniversitesi, Maltepe Üniversitesi |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Urea breath test Lansoprazole Rapid urease test Ranitidine bismuth citrate Ranitidine Gastroenterology Drug Administration Schedule Helicobacter Infections Young Adult Clarithromycin Internal medicine eradication Humans Medicine Endoscopy Digestive System Prospective Studies Dyspepsia Aged biology medicine.diagnostic_test Helicobacter pylori business.industry Amoxicillin Proton Pump Inhibitors Middle Aged biology.organism_classification lansoprazole Anti-Bacterial Agents Regimen Treatment Outcome Histamine H2 Antagonists Tolerability Drug Therapy Combination Female business Bismuth medicine.drug |
| DOI: | 10.4318/tjg.2013.0509 |
| Popis: | WOS: 000326481900003 PubMed ID: 24254262 Background/aims: Proton-pump inhibitor- and ranitidine bismuth citrate-based triple regimens are the two recommended first-line treatments for the eradication of Helicobacter pylori. We aimed to compare the effectiveness and tolerability of these two treatments in a prospective, multi-centric, randomized study. Materials and Methods: Patients with dyspeptic complaints were recruited from 15 study centers. Presence of Helicobacter pylori was investigated by both histology and rapid urease test. The patients were randomized to either ranitidine bismuth citrate 400 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=149) or lansoprazole 30 mg bid plus amoxicillin 1 g bid plus clarithromycin 500 mg bid (n=130) treatment arm for 14 days. Adverse events have been recorded during the treatment phase. A C-13 urea breath test was performed 6 weeks after termination of treatment to assess the efficacy of the therapy. Eradication rate was calculated by intention-to-treat and per-protocol analysis. Results: Two hundred seventy-nine patients (123 male, 156 female) were eligible for randomization. In per-protocol analysis (n=247), Helicobacter pylori was eradicated with ranitidine bismuth citrate- and lansoprazole-based regimens in 74,6% and 69,2% of cases, respectively (p>0,05). Intention-to-treat analysis (n=279) revealed that eradication rates were 65,1% and 63,6% in ranitidine bismuth citrate- and in lansoprazole-based regimens, respectively (p>0,05). Both regimes were well-tolerated, and no serious adverse event was observed during the study. Conclusion: Ranitidine bismuth citrate-based regimen is at least as effective and tolerable as the classical proton-pump inhibitor-based regimen, but none of the therapies could achieve the recommendable eradication rate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|